FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study

Not Applicable

Completed

Conditions: Human Papillomavirus Infection

Interventions: Behavioral: Healthcare Activity
Other: Communication Intervention
Other: Communication Skills Training
Other: Survey Administration

First Posted Date: 2020-12-09

Last Posted Date: 2024-10-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 42

Registration Number: NCT04660331

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Triple-Negative Breast Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Atezolizumab
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Biological: PD1 Inhibitor

First Posted Date: 2020-11-20

Last Posted Date: 2023-08-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04639245

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

Not Applicable

Active, not recruiting

Conditions: Clinical Stage II Cutaneous Melanoma AJCC v8
Hematopoietic and Lymphoid Cell Neoplasm
Invasive Malignant Neoplasm
Thyroid Gland Carcinoma
Lymphoma
Sarcoma
Stage I Colorectal Cancer AJCC v8
Stage II Colorectal Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8

Interventions: Other: Internet-Based Intervention
Other: Internet Mobile Technology
Other: Questionnaire Administration
Procedure: Supportive Care
Other: Informational Intervention

First Posted Date: 2020-10-19

Last Posted Date: 2024-10-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 556

Registration Number: NCT04593277

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: X-Ray Imaging

First Posted Date: 2020-10-08

Last Posted Date: 2024-11-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04579523

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Phase 2

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Hematologic and Lymphocytic Disorder

Interventions: Other: Quality-of-Life Assessment
Drug: Placebo Administration
Other: Questionnaire Administration
Biological: Ustekinumab

First Posted Date: 2020-10-01

Last Posted Date: 2024-06-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 116

Registration Number: NCT04572815

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
City of Hope Comprehensive Cancer Center,, Duarte, California, United States

and more 1 locations

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2
Myeloid Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2020-08-25

Last Posted Date: 2024-05-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04526288

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation

Phase 1

Completed

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Other: Health Promotion and Education
Behavioral: Smoking Cessation Intervention (Actify app)
Behavioral: Smoking Cessation Intervention (Current Standard Care app)
Other: Survey Administration

First Posted Date: 2020-08-25

Last Posted Date: 2024-03-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 242

Registration Number: NCT04525222

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

Not Applicable

Not yet recruiting

Conditions: Malignant Solid Neoplasm

Interventions: Other: Internet-Based Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2020-08-17

Last Posted Date: 2024-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 400

Registration Number: NCT04515810

Locations: 🇺🇸
Northwell Health, Manhasset, New York, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States

and more 1 locations

SmartQuit Program for Smoking Cessation

Not Applicable

Completed

Conditions: Tobacco-Related Carcinoma
Cigarette Smoking-Related Carcinoma

Interventions: Behavioral: SmartQuit Smoking and Tobacco Cessation Program
Other: Survey Administration

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 99

Registration Number: NCT04510077

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Website Smoking Cessation Intervention for the Promotion of Smoking Cessation in Low-Income Veterans

Phase 1

Completed

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Behavioral: Smoking Cessation Intervention (New website)
Behavioral: Smoking Cessation Intervention (Standard of care website)
Behavioral: Health Education
Other: Health Promotion and Education
Other: Questionnaire Administration

First Posted Date: 2020-08-06

Last Posted Date: 2023-04-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT04502524

Locations: 🇺🇸
Bedford VA Research Corporation, Inc., Bedford, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy